TY - STD TI - NCCN clinical practice guidelines in oncology (NCCN guidelines) non-small cell lung cancer, version 4; 2017. ID - ref1 ER - TY - JOUR AU - Gaughan, E. M. AU - Costa, D. B. PY - 2011 DA - 2011// TI - Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities JO - Ther Adv Med Oncol VL - 3 UR - https://doi.org/10.1177/1758834010397569 DO - 10.1177/1758834010397569 ID - Gaughan2011 ER - TY - JOUR AU - Sharma, S. V. AU - Bell, D. W. AU - Settleman, J. AU - Haber, D. A. PY - 2007 DA - 2007// TI - Epidermal growth factor receptor mutations in lung cancer JO - Nat Rev Cancer VL - 7 UR - https://doi.org/10.1038/nrc2088 DO - 10.1038/nrc2088 ID - Sharma2007 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. L. AU - Thongprasert, S. AU - Yang, C. H. AU - Chu, D. T. AU - Saijo, N. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Zhou, C. AU - Wu, Y. L. AU - Chen, G. AU - Feng, J. AU - Liu, X. Q. AU - Wang, C. PY - 2011 DA - 2011// TI - Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70184-X DO - 10.1016/S1470-2045(11)70184-X ID - Zhou2011 ER - TY - JOUR AU - Wen, Y. S. AU - Cai, L. AU - Zhang, X. W. AU - Zhu, J. F. AU - Zhang, Z. C. AU - Shao, J. Y. PY - 2014 DA - 2014// TI - Concurrent oncogene mutation profile in chinese patients with stage Ib lung adenocarcinoma JO - Medicine VL - 93 UR - https://doi.org/10.1097/MD.0000000000000296 DO - 10.1097/MD.0000000000000296 ID - Wen2014 ER - TY - JOUR AU - Huang, S. F. AU - Liu, H. P. AU - Li, L. H. AU - Ku, Y. C. AU - Fu, Y. N. AU - Tsai, H. Y. PY - 2004 DA - 2004// TI - High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-04-1245 DO - 10.1158/1078-0432.CCR-04-1245 ID - Huang2004 ER - TY - JOUR AU - Kobayashi, S. AU - Canepa, H. M. AU - Bailey, A. S. AU - Nakayama, S. AU - Yamaguchi, N. AU - Goldstein, M. A. PY - 2013 DA - 2013// TI - Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors JO - J Thorac Oncol VL - 8 UR - https://doi.org/10.1097/JTO.0b013e3182781e35 DO - 10.1097/JTO.0b013e3182781e35 ID - Kobayashi2013 ER - TY - JOUR AU - Zhang, G. C. AU - Lin, J. Y. AU - Wang, Z. AU - Zhou, Q. AU - Xu, C. R. AU - Zhu, J. Q. PY - 2007 DA - 2007// TI - Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients JO - Clin Oncol (R Coll Radiol) VL - 19 UR - https://doi.org/10.1016/j.clon.2007.04.006 DO - 10.1016/j.clon.2007.04.006 ID - Zhang2007 ER - TY - JOUR AU - Hsieh, M. H. AU - Fang, Y. F. AU - Chang, W. C. AU - Kuo, H. P. AU - Lin, S. Y. AU - Liu, H. P. PY - 2006 DA - 2006// TI - Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer JO - Lung Cancer VL - 53 UR - https://doi.org/10.1016/j.lungcan.2006.06.005 DO - 10.1016/j.lungcan.2006.06.005 ID - Hsieh2006 ER - TY - JOUR AU - Hata, A. AU - Yoshioka, H. AU - Fujita, S. AU - Kunimasa, K. AU - Kaji, R. AU - Imai, Y. PY - 2010 DA - 2010// TI - Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer JO - J Thorac Oncol VL - 5 UR - https://doi.org/10.1097/JTO.0b013e3181e8b3c5 DO - 10.1097/JTO.0b013e3181e8b3c5 ID - Hata2010 ER - TY - JOUR AU - Yokoyama, T. AU - Kondo, M. AU - Goto, Y. AU - Fukui, T. AU - Yoshioka, H. AU - Yokoi, K. PY - 2006 DA - 2006// TI - EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification JO - Cancer Sci VL - 97 UR - https://doi.org/10.1111/j.1349-7006.2006.00233.x DO - 10.1111/j.1349-7006.2006.00233.x ID - Yokoyama2006 ER - TY - JOUR AU - Su, K. Y. AU - Chen, H. Y. AU - Li, K. C. AU - Kuo, M. L. AU - Yang, J. C. AU - Chan, W. K. PY - 2012 DA - 2012// TI - Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.38.3224 DO - 10.1200/JCO.2011.38.3224 ID - Su2012 ER - TY - JOUR AU - Keam, B. AU - Kim, D. W. AU - Park, J. H. AU - Lee, J. O. AU - Kim, T. M. AU - Lee, S. H. PY - 2014 DA - 2014// TI - Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer JO - Int J Clin Oncol VL - 19 UR - https://doi.org/10.1007/s10147-013-0602-1 DO - 10.1007/s10147-013-0602-1 ID - Keam2014 ER - TY - JOUR AU - Liu, Y. AU - Wu, B. Q. AU - Zhong, H. H. AU - Hui, P. AU - Fang, W. G. PY - 2013 DA - 2013// TI - Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing JO - Int J Clin Exp Pathol VL - 6 ID - Liu2013 ER - TY - JOUR AU - Xu, J. AU - Jin, B. AU - Chu, T. AU - Dong, X. AU - Yang, H. AU - Zhang, Y. PY - 2016 DA - 2016// TI - EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: a real-world study in China JO - Lung Cancer VL - 96 UR - https://doi.org/10.1016/j.lungcan.2016.01.018 DO - 10.1016/j.lungcan.2016.01.018 ID - Xu2016 ER - TY - JOUR AU - Wu, J. Y. AU - Yu, C. J. AU - Chang, Y. C. AU - Yang, C. H. AU - Shih, J. Y. AU - Yang, P. C. PY - 2011 DA - 2011// TI - Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-3408 DO - 10.1158/1078-0432.CCR-10-3408 ID - Wu2011 ER - TY - JOUR AU - Chen, D. AU - Song, Z. AU - Cheng, G. PY - 2016 DA - 2016// TI - Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations JO - Onco Targets Ther VL - 9 UR - https://doi.org/10.2147/OTT.S108242 DO - 10.2147/OTT.S108242 ID - Chen2016 ER - TY - JOUR AU - Klughammer, B. AU - Brugger, W. AU - Cappuzzo, F. AU - Ciuleanu, T. AU - Mok, T. AU - Reck, M. PY - 2016 DA - 2016// TI - Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2015.12.107 DO - 10.1016/j.jtho.2015.12.107 ID - Klughammer2016 ER - TY - JOUR AU - Kempf, E. AU - Lacroix, L. AU - Soria, J. C. PY - 2015 DA - 2015// TI - First reported case of unexpected response to an epidermal growth factor receptor tyrosine kinase inhibitor in the I744M uncommon EGFR mutation JO - Clin Lung Cancer VL - 16 UR - https://doi.org/10.1016/j.cllc.2015.06.002 DO - 10.1016/j.cllc.2015.06.002 ID - Kempf2015 ER - TY - JOUR AU - Wu, S. G. AU - Chang, Y. L. AU - Hsu, Y. C. AU - Wu, J. Y. AU - Yang, C. H. AU - Yu, C. J. PY - 2008 DA - 2008// TI - Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern JO - Oncologist VL - 13 UR - https://doi.org/10.1634/theoncologist.2008-0093 DO - 10.1634/theoncologist.2008-0093 ID - Wu2008 ER - TY - JOUR AU - Frega, S. AU - Conte, P. AU - Fassan, M. AU - Polo, V. AU - Pasello, G. PY - 2016 DA - 2016// TI - A triple rare E709K and L833V/H835L EGFR mutation responsive to an irreversible Pan-HER inhibitor: a case report of lung adenocarcinoma treated with afatinib JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.01.023 DO - 10.1016/j.jtho.2016.01.023 ID - Frega2016 ER - TY - JOUR AU - Yang, T. Y. AU - Tsai, C. R. AU - Chen, K. C. AU - Hsu, K. H. AU - Lee, H. M. AU - Chang, G. C. PY - 2011 DA - 2011// TI - Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.5802 DO - 10.1200/JCO.2010.33.5802 ID - Yang2011 ER - TY - JOUR AU - Leventakos, K. AU - Kipp, B. R. AU - Rumilla, K. M. AU - Winters, J. L. AU - Yi, E. S. AU - Mansfield, A. S. PY - 2016 DA - 2016// TI - S768I mutation in EGFR in patients with lung cancer JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.05.007 DO - 10.1016/j.jtho.2016.05.007 ID - Leventakos2016 ER - TY - JOUR AU - Arcila, M. E. AU - Nafa, K. AU - Chaft, J. E. AU - Rekhtman, N. AU - Lau, C. AU - Reva, B. A. PY - 2013 DA - 2013// TI - EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.MCT-12-0620 DO - 10.1158/1535-7163.MCT-12-0620 ID - Arcila2013 ER - TY - JOUR AU - Asahina, H. AU - Yamazaki, K. AU - Kinoshita, I. AU - Yokouchi, H. AU - Dosaka-Akita, H. AU - Nishimura, M. PY - 2006 DA - 2006// TI - Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L JO - Lung Cancer VL - 54 UR - https://doi.org/10.1016/j.lungcan.2006.09.005 DO - 10.1016/j.lungcan.2006.09.005 ID - Asahina2006 ER - TY - JOUR AU - Yasuda, H. AU - Kobayashi, S. AU - Costa, D. B. PY - 2012 DA - 2012// TI - EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70129-2 DO - 10.1016/S1470-2045(11)70129-2 ID - Yasuda2012 ER - TY - JOUR AU - Lund-Iversen, M. AU - Kleinberg, L. AU - Fjellbirkeland, L. AU - Helland, Å. AU - Brustugun, O. T. PY - 2012 DA - 2012// TI - Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations JO - J Thorac Oncol VL - 7 UR - https://doi.org/10.1097/JTO.0b013e3182614a9d DO - 10.1097/JTO.0b013e3182614a9d ID - Lund-Iversen2012 ER - TY - JOUR AU - Kancha, R. K. AU - Bubnoff, N. AU - Peschel, C. AU - Duyster, J. PY - 2009 DA - 2009// TI - Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-1757 DO - 10.1158/1078-0432.CCR-08-1757 ID - Kancha2009 ER - TY - JOUR AU - Riely, G. J. AU - Politi, K. A. AU - Miller, V. A. AU - Pao, W. PY - 2006 DA - 2006// TI - Update on epidermal growth factor receptor mutations in non-small cell lung cancer JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0658 DO - 10.1158/1078-0432.CCR-06-0658 ID - Riely2006 ER - TY - JOUR AU - Balak, M. N. AU - Gong, Y. AU - Riely, G. J. AU - Somwar, R. AU - Li, A. R. AU - Zakowski, M. F. PY - 2006 DA - 2006// TI - Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-1570 DO - 10.1158/1078-0432.CCR-06-1570 ID - Balak2006 ER - TY - JOUR AU - Zhang, Y. AU - Wang, Z. AU - Hao, X. AU - Hu, X. AU - Wang, H. AU - Wang, Y. PY - 2017 DA - 2017// TI - Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations JO - Chin J Cancer Res VL - 29 UR - https://doi.org/10.21147/j.issn.1000-9604.2017.01.03 DO - 10.21147/j.issn.1000-9604.2017.01.03 ID - Zhang2017 ER - TY - JOUR AU - Zhu, X. AU - Bai, Q. AU - Lu, Y. AU - Qi, P. AU - Ding, J. AU - Wang, J. PY - 2017 DA - 2017// TI - Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I: a retrospective analysis and literature review JO - Target Oncol VL - 12 UR - https://doi.org/10.1007/s11523-016-0455-4 DO - 10.1007/s11523-016-0455-4 ID - Zhu2017 ER - TY - JOUR AU - Wu, J. Y. AU - Shih, J. Y. PY - 2016 DA - 2016// TI - Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer JO - Onco Targets Ther VL - 9 UR - https://doi.org/10.2147/OTT.S118071 DO - 10.2147/OTT.S118071 ID - Wu2016 ER - TY - JOUR AU - Yang, Y. AU - Zhang, B. AU - Li, R. AU - Liu, B. AU - Wang, L. PY - 2016 DA - 2016// TI - EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: a case report and review of the literature JO - Oncol Lett VL - 11 UR - https://doi.org/10.3892/ol.2016.4409 DO - 10.3892/ol.2016.4409 ID - Yang2016 ER - TY - JOUR AU - Svaton, M. AU - Pesek, M. AU - Chudacek, Z. AU - Vosmiková, H. PY - 2015 DA - 2015// TI - Current two EGFR mutations in lung adenocarcinoma—case report JO - Klin Onkol VL - 28 UR - https://doi.org/10.14735/amko2015134 DO - 10.14735/amko2015134 ID - Svaton2015 ER - TY - JOUR AU - Peng, L. AU - Song, Z. AU - Jiao, S. PY - 2015 DA - 2015// TI - Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation JO - Onco Targets Ther VL - 8 ID - Peng2015 ER - TY - JOUR AU - Baek, J. H. AU - Sun, J. M. AU - Min, Y. J. AU - Cho, E. K. AU - Cho, B. C. AU - Kim, J. H. PY - 2015 DA - 2015// TI - Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea JO - Lung Cancer VL - 87 UR - https://doi.org/10.1016/j.lungcan.2014.11.013 DO - 10.1016/j.lungcan.2014.11.013 ID - Baek2015 ER - TY - JOUR AU - Peng, L. AU - Song, Z. G. AU - Jiao, S. C. PY - 2014 DA - 2014// TI - Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations JO - Sci Rep VL - 4 UR - https://doi.org/10.1038/srep06104 DO - 10.1038/srep06104 ID - Peng2014 ER - TY - JOUR AU - Chung, K. P. AU - Shih, J. Y. AU - Yu, C. J. PY - 2010 DA - 2010// TI - Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2010.28.6260 DO - 10.1200/JCO.2010.28.6260 ID - Chung2010 ER - TY - JOUR AU - Yang, C. H. AU - Yu, C. J. AU - Shih, J. Y. AU - Chang, Y. C. AU - Hu, F. C. AU - Tsai, M. C. PY - 2008 DA - 2008// TI - Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.6695 DO - 10.1200/JCO.2007.15.6695 ID - Yang2008 ER - TY - JOUR AU - Ichihara, S. AU - Toyooka, S. AU - Fujiwara, Y. AU - Hotta, K. AU - Shigematsu, H. AU - Tokumo, M. PY - 2007 DA - 2007// TI - The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer JO - Int J Cancer VL - 120 UR - https://doi.org/10.1002/ijc.22513 DO - 10.1002/ijc.22513 ID - Ichihara2007 ER - TY - JOUR AU - Pugh, T. J. AU - Bebb, G. AU - Barclay, L. AU - Sutcliffe, M. AU - Fee, J. AU - Salski, C. PY - 2007 DA - 2007// TI - Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients JO - BMC Cancer VL - 7 UR - https://doi.org/10.1186/1471-2407-7-128 DO - 10.1186/1471-2407-7-128 ID - Pugh2007 ER - TY - JOUR AU - Kimura, H. AU - Suminoe, M. AU - Kasahara, K. AU - Sone, T. AU - Araya, T. AU - Tamori, S. PY - 2007 DA - 2007// TI - Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) JO - Br J Cancer VL - 97 UR - https://doi.org/10.1038/sj.bjc.6603949 DO - 10.1038/sj.bjc.6603949 ID - Kimura2007 ER - TY - JOUR AU - Zandwijk, N. AU - Mathy, A. AU - Boerrigter, L. AU - Ruijter, H. AU - Tielen, I. PY - 2007 DA - 2007// TI - EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer JO - Ann Oncol VL - 18 UR - https://doi.org/10.1093/annonc/mdl323 DO - 10.1093/annonc/mdl323 ID - Zandwijk2007 ER - TY - JOUR AU - Jackman, D. M. AU - Yeap, B. Y. AU - Lindeman, N. I. AU - Fidias, P. AU - Rabin, M. S. AU - Temel, J. PY - 2007 DA - 2007// TI - Phase II clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.07.5754 DO - 10.1200/JCO.2006.07.5754 ID - Jackman2007 ER - TY - JOUR AU - Pallis, A. G. AU - Voutsina, A. AU - Kalikaki, A. AU - Souglakos, J. AU - Briasoulis, E. AU - Murray, S. PY - 2007 DA - 2007// TI - ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer JO - Br J Cancer VL - 97 UR - https://doi.org/10.1038/sj.bjc.6604068 DO - 10.1038/sj.bjc.6604068 ID - Pallis2007 ER - TY - JOUR AU - Han, S. W. AU - Kim, T. Y. AU - Jeon, Y. K. AU - Hwang, P. G. AU - Im, S. A. AU - Lee, K. H. PY - 2006 DA - 2006// TI - Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-05-2845 DO - 10.1158/1078-0432.CCR-05-2845 ID - Han2006 ER - TY - JOUR AU - Kosaka, T. AU - Yatabe, Y. AU - Endoh, H. AU - Yoshida, K. AU - Hida, T. AU - Tsuboi, M. PY - 2006 DA - 2006// TI - Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0714 DO - 10.1158/1078-0432.CCR-06-0714 ID - Kosaka2006 ER - TY - JOUR AU - Choong, N. W. AU - Dietrich, S. AU - Seiwert, T. Y. AU - Tretiakova, M. S. AU - Nallasura, V. AU - Davies, G. C. PY - 2006 DA - 2006// TI - Gefitinib response of erlotinib-refractory lung cancer involving meninges–role of EGFR mutation JO - Nat Clin Pract Oncol VL - 3 UR - https://doi.org/10.1038/ncponc0400 DO - 10.1038/ncponc0400 ID - Choong2006 ER - TY - JOUR AU - Oshita, F. AU - Matsukuma, S. AU - Yoshihara, M. AU - Sakuma, Y. AU - Ohgane, N. AU - Kameda, Y. PY - 2006 DA - 2006// TI - Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer JO - Br J Cancer VL - 95 UR - https://doi.org/10.1038/sj.bjc.6603396 DO - 10.1038/sj.bjc.6603396 ID - Oshita2006 ER - TY - JOUR AU - Tokumo, M. AU - Toyooka, S. AU - Ichihara, S. AU - Ohashi, K. AU - Tsukuda, K. AU - Ichimura, K. PY - 2006 DA - 2006// TI - Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer JO - Lung Cancer VL - 53 UR - https://doi.org/10.1016/j.lungcan.2006.04.008 DO - 10.1016/j.lungcan.2006.04.008 ID - Tokumo2006 ER - TY - JOUR AU - Chou, T. Y. AU - Chiu, C. H. AU - Li, L. H. AU - Hsiao, C. Y. AU - Tzen, C. Y. AU - Chang, K. T. PY - 2005 DA - 2005// TI - Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-1981 DO - 10.1158/1078-0432.CCR-04-1981 ID - Chou2005 ER - TY - JOUR AU - Shih, J. Y. AU - Gow, C. H. AU - Yu, C. J. AU - Yang, C. H. AU - Chang, Y. L. AU - Tsai, M. F. PY - 2006 DA - 2006// TI - Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer JO - Int J Cancer VL - 118 UR - https://doi.org/10.1002/ijc.21458 DO - 10.1002/ijc.21458 ID - Shih2006 ER - TY - JOUR AU - Taron, M. AU - Ichinose, Y. AU - Rosell, R. AU - Mok, T. AU - Massuti, B. AU - Zamora, L. PY - 2005 DA - 2005// TI - Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2618 DO - 10.1158/1078-0432.CCR-04-2618 ID - Taron2005 ER - TY - JOUR AU - Mitsudomi, T. AU - Kosaka, T. AU - Endoh, H. AU - Horio, Y. AU - Hida, T. AU - Mori, S. PY - 2005 DA - 2005// TI - Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non–small-cell lung cancer with postoperative recurrence JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.00.992 DO - 10.1200/JCO.2005.00.992 ID - Mitsudomi2005 ER - TY - JOUR AU - Takano, T. AU - Ohe, Y. AU - Sakamoto, H. AU - Tsuta, K. AU - Matsuno, Y. AU - Tateishi, U. PY - 2005 DA - 2005// TI - Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.01.0793 DO - 10.1200/JCO.2005.01.0793 ID - Takano2005 ER - TY - JOUR AU - Pao, W. AU - Miller, V. AU - Zakowski, M. AU - Doherty, J. AU - Politi, K. AU - Sarkaria, I. PY - 2004 DA - 2004// TI - EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib JO - Proc Natl Acad Sci USA VL - 101 UR - https://doi.org/10.1073/pnas.0405220101 DO - 10.1073/pnas.0405220101 ID - Pao2004 ER -